Replies to post #485 on BioVie Inc (BIVI)

[someconcerns]

Not sure how the studies are progressing on BIV201, but their last 8k (see above) stated that they had reacquired certain rights for terlipressin.

item 2.01 Completion of Acquisition or Disposition of Assets

On December 24, 2018, BioVie Inc. (“BioVie”) completed the return of its partial ownership rights in a modified terlipressin program of PharmaIN Corporation (“ PharmaIN ”) and paid to PharmaIN the remaining $10,844 balance on a related debt for past services and other matters. BioVie had acquired the rights in that program, which is separate from and unrelated to the current BIV201 clinical development program, under a 2016 Commercialization Agreement with PharmaIN.

To me, that is not something I would do if I were staring at a brick wall. I think they are proceeding as to plan.